Partnering

Partnering

At Leapfrog Bio, we collaborate with pharmaceutical and biotechnology companies to unlock hidden value from shelved or deprioritized assets by applying our OncoSLX platform to identify new, genetically defined patient populations.

We offer a range of flexible partnership models tailored to the needs of our collaborators, including:

• Portfolio screening and target matching using our OncoSLX Platform to identify compounds with potential in novel oncology indications
• R&D libraries and discovery-stage assets

We actively evaluate:

• Pre-clinical and clinical product candidates that may benefit from genetic retargeting
• R&D libraries and discovery-stage assets
• Shelved or legacy programs with unrealized oncology applications

Please contact bd@leapfrog.bio for more information.